Amgen - revenue from Enbrel worldwide by region 2011-2023
This statistic displays the revenue that Amgen received through Enbrel worldwide by region from 2011 to 2023, in million U.S. dollars. In 2023, Enbrel generated 3.7 billion U.S. dollars of revenue in total. Enbrel is a biopharmaceutical product that is used to treat autoimmune diseases. It is marketed as a powder or a pre-mixed liquid. Previously, Enbrel was promoted by both Amgen and Pfizer in the United States and Canada. Since November 2016, the FDA approved the expanded use of Enbrel as a drug to treat pediatric patients (ages 4-17) with chronic moderate-to-severe plaque psoriasis.